Traders should monitor for any upcoming earnings releases or clinical trial updates that may have prompted this monetization. The absence of purchases and concentration of sales among executives may signal lack of near-term conviction, especially given elevated stock price (~$80). Consider this a cautionary signal ahead of potential volatility.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 23 $76.96entry
- T+1 · 8mo ago −3.30%α −2.96% · $74.42
- T+5 · 8mo ago +3.27%α +6.85% · $79.48
- T+20 · 7mo ago +14.44%α +7.01% · $88.07
- T+60 · 5mo ago +16.81%α +3.76% · $89.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kymera Therapeutics COO Chadwick Jeremy G conducted a series of derivative exercises and open-market sales over the past week, generating approximately $3.73 million in proceeds from the sale of 47,483 shares. Director Pamela Esposito also sold 700 shares for $54,400, following option exercises. The activity is concentrated among senior insiders, with the majority of economic impact coming from open-market sales.
Key Financial Metrics
Key Facts
- COO Chadwick Jeremy G sold 47,483 shares in open-market transactions for total proceeds of ~$3.73M ($1.98M on March 25 at $80.26, $1.75M on March 23 at $76.73).
- All sales were preceded by derivative (option) exercises; some at $0 cost basis indicate incentive grants being monetized.
- Director Pamela Esposito sold 700 shares for $54,400 following exercise of 2,500 options at $49.10 strike price.
- Total open-market sale value from cluster: ~$3.79M (including prior 30-day activity), representing 0.06% of $6.1B market cap, modest in scale but notable due to C-suite participation.
- No open-market purchases or insider buying activity observed.
Financial Impact
$3.79M in insider sales over 7 days, with $3.73M from COO alone; represents 0.06% of market cap
Risk Factors
- Perception of insider pessimism due to lack of offsetting buys and timing of sales at current price levels.
- Potential for further selling if other insiders follow suit.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (9 trades, 7d window) | cluster-KYMR-1774473338973 |
Track record
37 reports on KYMR
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 8 of 13 went positive at some point.
Filters
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
- Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers